PFIZER ANNOUNCES PHASE 3 TOP-LINE RESULTS FOR RIVIPANSEL IN PATIENTS WITH SICKLE CELL DISEASE EXPERIENCING A VASO-OCCLUSIVE CRISIS

Pfizer Inc. (NYSE:PFE) announced  that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.…

View More PFIZER ANNOUNCES PHASE 3 TOP-LINE RESULTS FOR RIVIPANSEL IN PATIENTS WITH SICKLE CELL DISEASE EXPERIENCING A VASO-OCCLUSIVE CRISIS

CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive…

View More CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer

ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today submitted a New Drug Application…

View More ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV